Advanced manufacturing research supports automated production of critical API
Study highlights potential of novel system for continuous, automated production of albuterol sulfate, an API on the US FDA’s drug shortage list.
List view / Grid view
Study highlights potential of novel system for continuous, automated production of albuterol sulfate, an API on the US FDA’s drug shortage list.
Research findings support the design of robust microbial processes for pharmaceutical products.
UK biotech commits to scale up of 228Th extraction and a long-term supply agreement to facilitate production of thousands of doses of 212Pb for cancer therapies annually.
The companies’ partnership covers messenger RNA design and production services.
R&D projects supported by the Centre for Process Innovation (CPI) aim to shape a sustainable, resilient and competitive future for pharma manufacturing.
Study demonstrates the non-invasive tool’s potential for real-time monitoring of cytomegalovirus (CMV) viral particles.
The CDMO’s programme, presented at CPHI Frankfurt 2025, combines responsiveness to new demand and operational rigour without jeopardising supply.
The right packaging is critical when it comes to preserving the quality, efficacy and safety of pharmaceutical and nutraceutical products. Here, Uwe Raupbach, R&D Engineer Desiccants, Sanner GmbH, answers some key questions about the need for environmental management in packaging, focusing on moisture and odour control, and the solutions available…
EPR Issue 3 includes articles on microbiology, downstream processing, manufacturing, drug formulation and more.
Contracts to use a facility at Fujifilm’s North Carolina site as part of moves to onshore its manufacturing.
The scheme will provide more support and a streamlined application process to companies constructing new US facilities.
The novel approach could reduce the industry’s reliance on fossil fuels by offering a sustainable production alternative for pharmaceuticals.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
The landmark regulation establishes a future where highly personalised treatments are part of routine care, says MHRA’s Chief Executive.
After their recent webinar, European Pharmaceutical Review’s Head of Content Ian Betteridge spoke with the team at Adragos Pharma to discuss the role of a CDMO and their importance in the fill and finish sector.